UWUshma Wadia

Ushma Wadia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ushma Wadia has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact and effectiveness of Australia's 2025 hybrid RSV immunisation program: results from the PAEDS-FluCAN Network

    by Ushma Wadia, Peter C. Richmond, Philip N. Britton, Jeremy Carr, Julia E. Clark, Nigel W. Crawford, Te-Yu Hung, Helen S. Marshall, Kristine K. Macartney, Nicholas J. Wood, et al.


  • Open Access

    Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial

    by Madeline M. Ong, Anita H.J. van Den Biggelaar, Leonard Goh, Heidi Hutton, Librada Fortuna, Vilasinee Yuwaree, Chawanee Kerdsomboon, Souad Mansouri, Pham Hong Thai, Peter C. Richmond, et al.


  • Open Access

    Impact and Effectiveness of Australia’s 2025 hybrid RSV Immunisation Program: Results from the PAEDS-FluCAN Network

    by Ushma Wadia, Peter Richmond, Philip Britton, Jeremy P. Carr, Julia E. Clark, Nigel W. Crawford, Te-Yu Hung, Helen S. Marshall, Kristine Macartney, Nick Wood, et al.

    Background: Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network.Methods: Thirteen national sentinel PAEDS-FluCAN network hospitals contributed paediatric RSV data. From April 2024 and November 2025, hospitalised children with RSV-associated acute respiratory infection (ARI; cases) and contemporaneous RSV-negative controls were recruited. Immunisation effectiveness was estimated using a test-negative design with multivariable regression, adjusted for prespecified covariates, and calculated as (1−adjusted odds ratio)×100% with 95% confidence intervals (CIs). Impact was assessed as the 2024–2025 change in the cumulative number of RSV hospitalisations during epidemiological weeks 14–48, excluding hospitals in two states with comprehensive 2024 nirsevimab programs, and stratified by age group.Findings: Between 1 January and 31 November 2025, 3743 children were recruited (2719 RSV-positive cases; 1024 test-negative controls). Overall effectiveness against RSV-associated ARI hospitalisation in the RSV-MIPP newborn cohort (born from 17 February) was 82·0% (95% CI: 70·0,89·2). Effectiveness estimates for maternal vaccination and nirsevimab were 80·8% (67·8, 88·6) and 89·5% (73·4, 95·8) respectively. Nirsevimab effectiveness in the catch-up cohort (born 1st October 2024 to 16th February 2025) was 87·3% (63·8, 95·5). The program’s impact was associated with 43·8%, 20·1% and 8·5% reduction in hospitalisations in infants aged 0 to <3months, 3 to <6months and 6 to 12months respectively.Interpretation: These first southern hemisphere estimates of a hybrid RSV prevention program demonstrated high effectiveness against RSV hospitalisation over a single season. Longitudinal evaluation of the RSV-MIPP is needed to understand sustained effectiveness and year-round population level impacts.


  • Open Access

    Impact and Effectiveness of Australia's 2025 Hybrid RSV Immunisation Program: Results from the PAEDS-FluCAN Network

    by Ushma Wadia, Peter Richmond, Philip Britton, Jeremy P. Carr, Julia E. Clark, Nigel W. Crawford, Te-Yu Hung, Helen S. Marshall, Kristine Macartney, Nick Wood, et al.

    Background: Australia introduced a hybrid Respiratory Syncytial Virus (RSV) Maternal and Infant Protection Program (RSV-MIPP) in 2025, using National Immunisation Program-funded RSV vaccine for pregnant people from 28 weeks' gestation and jurisdiction-funded nirsevimab. We estimated real-world effectiveness and assessed the impact of the RSV-MIPP program across a participating surveillance network. Methods: Thirteen national sentinel PAEDS-FluCAN network hospitals contributed paediatric RSV data. From April 2024 and November 2025, hospitalised children with RSV-associated acute respiratory infection (ARI; cases) and contemporaneous RSV-negative controls were recruited. Immunisation effectiveness was estimated using a test-negative design with multivariable regression, adjusted for prespecified covariates, and calculated as (1−adjusted odds ratio)×100% with 95% confidence intervals (CIs). Impact was assessed as the 2024–2025 change in the cumulative number of RSV hospitalisations during epidemiological weeks 14–48, excluding hospitals in two states with comprehensive 2024 nirsevimab programs, and stratified by age group. Findings: Between 1 January and 31 November 2025, 3743 children were recruited (2719 RSV-positive cases; 1024 test-negative controls). Overall effectiveness against RSV-associated ARI hospitalisation in the RSV-MIPP newborn cohort (born from 17 February) was 82·0% (95% CI: 70·0,89·2). Effectiveness estimates for maternal vaccination and nirsevimab were 80·8% (67·8, 88·6) and 89·5% (73·4, 95·8) respectively. Nirsevimab effectiveness in the catch-up cohort (born 1st October 2024 to 16th February 2025) was 87·3% (63·8, 95·5). The program’s impact was associated with 43·8%, 20·1% and 8·5% reduction in hospitalisations in infants aged 0 to <3months, 3 to <6months and 6 to 12months respectively. Interpretation: These first southern hemisphere estimates of a hybrid RSV prevention program demonstrated high effectiveness against RSV hospitalisation over a single season. Longitudinal evaluation of the RSV-MIPP is needed to understand sustained effectiveness and year-round population level impacts. Funding: This work was sponsored by the Australian Government Department of Health, Disability and Ageing.

  • Open Access

    Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS)

    by Christopher C Blyth, Ushma Wadia, Philip N Britton, Jeremy Carr, Julia E Clark, Nigel W Crawford, Te-Yu Hung, Kristine K Macartney, Helen S Marshall, Nicholas J Wood, et al.

    BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of morbidity and mortality in young children and older adults. A long-acting anti-RSV monoclonal antibody (nirsevimab) and bivalent pre-fusion F-protein pregnancy vaccine became available to prevent RSV in young children in 2024; two RSV vaccines for adults ≥ 60 years were also available. AIM: To report 2024 RSV epidemiology in Australia, identify risk factors for severe outcomes, and use and effectiveness of RSV immunisation products. METHODS: National sentinel hospital-based RSV surveillance was established in 2024, recruiting hospitalised laboratory-confirmed RSV cases and test-negative controls from 22 sites in a national hospital network (FluCAN-PAEDS). RESULTS: Between April and December 2024, 3,998 subjects (3,415 children; 582 adults) were hospitalised with RSV. Most cases were infants < 12 months (n = 1,534; 38.4%); 1,661 (41.5%) had underlying medical conditions. Children < 6 months, First Nations children, those born preterm or with underlying medical conditions (cardiac, neurological, genetic and metabolic disease/disorders, immunosuppression) were at greatest risk of severe outcomes. Severe outcomes were more frequent in adults with malignancy, respiratory or cardiac disease. Nirsevimab effectiveness against hospitalisation in infants < 12 months in the two Australian jurisdictions with population-wide immunisation programmes was 83.1% (95% CI: 67.4–91.3). RSV vaccine use (pregnancy; adults ≥ 60 years) was limited, precluding effectiveness assessments. CONCLUSION: National surveillance enabled timely 2024 data collection with the capability to evaluate effectiveness of immunisation products preventing RSV. Nirsevimab demonstrated comparable effectiveness to that in the northern hemisphere, informing Australia’s 2025 strategy. Evaluation to assess the impact of more widespread uptake of RSV prevention products continues.


  • Open Access

    Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)‐associated hospitalisations, Western Australia, 2024: a population‐based analysis

    by Lauren E Bloomfield, Nevada V Pingault, Rachel E Foong, Sarah French, Jo‐Anne Morgan, Ushma Wadia, Hannah C Moore, Christopher C Blyth, Peter C Richmond, Paul K Armstrong, et al.


  • Open Access

    Optimising COVID-19 Episode Identification Using Serology and PCR/Rapid Antigen Testing: Insights from the BRACE Trial

    by Ellie McDonald, Laure F. Pittet, Marc Bonten, Anthony Byrne, John Campbell, Julio Croda, Margareth Pretti Dalcolmo, Andrew Davidson, Glauce dos Santos, Kaya Gardiner, et al.

    Background: Accurately identifying COVID-19 episodes was crucial during the pandemic for evaluating interventions. Results from diagnostic tools like PCR, rapid antigen test (RAT) and serology are affected by factors such as timing of tests and vaccination status. The BRACE trial developed an algorithm integrating these diagnostic tools for illness episode classification. Methods: In the BRACE trial, 3988 participants reported 5512 febrile/respiratory illness episodes and provided longitudinal blood samples over one year. SARS-CoV-2 diagnosis relied on a three-component algorithm: (1) a serology algorithm assessing anti-SARS-CoV-2 nucleocapsid antibody seroconversion, (2) a PCR/RAT algorithm, and (3) an episode interpretation algorithm combining serology and PCR/RAT results to categorise episodes as COVID-19, Not COVID-19 or Uncertain. The algorithms accounted for vaccination status and timing of testing relative to symptom onset to refine episode classifications. Results: Of 5512 illness episodes, 890 (16%) were classified as COVID-19, 3852 (70%) as Not COVID-19, and 770 (14%) as Uncertain. Compared to relying solely on PCR/RAT results, integrating serology in the algorithm reduced the proportion of Uncertain classifications by more than half. Among the COVID-19 episodes, 89% were identified by positive PCR/RAT results, and the remaining 11% (with missing or negative PCR/RAT tests) were identified by serology. Discordance between PCR/RAT and serology occurred in 13% of episodes. Conclusion: An algorithm integrating PCR/RAT and serology results in the context of test timing and vaccine status enabled the accurate identification of COVID-19 episodes and minimised the number of episodes that would otherwise have been classified as Uncertain.

  • Top Cited Papers
    Open Access

    Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

    by Ushma Wadia, Hannah C. Moore, Peter C. Richmond, Avram Levy, Lana Bell, Catherine Pienaar, Joanne Harvey, Caroline Finucane, Erin van der Helder, Lauren Bloomfield, et al.


  • Open Access

    Immunogenicity of co-administered vaccine antigens with whole-cell or acellular pertussis vaccines in infancy: a randomised controlled trial

    by Gladymar Pérez Chacón, Sonia McAlister, James Totterdell, Marie J. Estcourt, Julie A. Marsh, Mark Jones, Kirsten P. Perrett, Dianne E. Campbell, Nicholas Wood, Michael Gold, et al.

    Summary: Background: Whole-cell pertussis (wP) and acellular pertussis (aP) vaccines evoke different immune responses to pertussis vaccine antigens. We compared the effect of a heterologous wP/aP/aP primary series (hereafter mixed wP/aP) versus a homologous aP/aP/aP primary schedule (hereafter aP-only) on antibody responses to co-administered vaccine antigens in infants and toddlers. Methods: We randomised Australian infants in a 1:1 ratio to receive either a mixed wP/aP schedule (pentavalent diphtheria-tetanus-wP-hepatitis B- Haemophilus influenzae type b; DTwP-HepB-Hib vaccine at 6 weeks old followed by hexavalent DTaP-inactivated poliovirus vaccine (IPV)-HepB-Hib vaccine at 4 and 6 months old) or to aP-only priming doses of hexavalent DTaP-IPV-HepB-Hib vaccine at the same ages. All infants received 13-valent pneumococcal conjugate vaccine (13vPCV) at 6 weeks, 4 and 12 months of age and DTaP-IPV and Hib vaccine boosters at 18 months. We estimated the ratio (GMR) of IgG geometric mean concentrations (GMCs) in the wP/aP and aP-only groups for the serotypes included in the 13vPCV, for Hib capsular polysaccharide polyribosylribitol phosphate (PRP), and for hepatitis B surface antigen (HBsAg) at 6, 7, 18, and 19 months. We assessed whether the wP/aP schedule is non-inferior to the aP-only schedule for co-administered vaccine antigens (GMR>2/3). Trial registration: ACTRN12617000065392p. Results: Between March 2018 and January 2020, 150 infants were randomised (75 per study arm). Responses to all 13vPCV serotypes and Hib-PRP at 6, 7, 18, and 19 months old, as well as HBsAg at 6 and 7 months old were non-inferior (>90% probability). Sera GMCs were higher for each 13vPCV serotype, Hib-PRP, and HBsAg at each timepoint in the wP/aP group than in the aP-only group. Interpretation: A mixed wP/aP schedule resulted in non-inferior IgG responses to co-administered vaccine antigens compared to the standard aP-only schedule for pertussis primary immunisation. Funding: Telethon New Children’s Hospital Research Fund and National Health and Medical Research Council. Research in context: Evidence before this study: Combination vaccines incorporate antigens that protect against multiple diseases into a single injection. Most low- and middle-income countries (LMICs) currently use wP combination vaccines. Due to the need for periodic boosters to protect older children, adolescents, and adults, these countries may consider moving to the less reactogenic aP combination vaccines that are routinely used in most high-income countries. We searched for evidence about whether a mixed wP/aP primary schedule impacts the immunogenicity of co-administered vaccines. We were particularly interested in evidence for impacts on 13vPCV 2 + 1 schedule and other pneumococcal dose-sparing schedules. We searched PubMed on May 23, 2024, for randomised controlled trials using the following search terms “pneumococcal”, “routine vaccin*”, and “pertussis” combined with Boolean operators, without date or language restrictions. We failed to identify any head-to-head randomised comparisons of the effect of heterologous (mixed) versus homologous pertussis vaccine primary series on co-administered vaccine antigens. Our previous meta-analysis reviewed 15 randomised controlled studies that compared serious adverse events among infants receiving wP versus aP as a first dose before 6 months of age. Few studies reported immune responses to non-DTP co-administered antigens. These findings suggest enhanced Hib responses among recipients of a three-dose primary series of wP compared to those who received three primary aP doses, non-inferior Hib-PRP seroprotection among aP compared to wP vaccinees, and mixed results regarding HBsAg-IgG levels post-wP priming. Both wP and aP groups exhibited weaker Hib-PRP IgG responses when DTP-Hib vaccines were co-administered with meningococcal serogroup C vaccine conjugated to cross-reactive material 197 (CRM 197 ) compared to the meningococcal serogroup C vaccine conjugated to tetanus toxoid (TT). Added value of this study: This paper is the first reported evidence of a mixed wP/aP schedule resulting in non-inferior IgG responses to co-administered vaccine antigens compared to the standard homologous aP-only schedule for pertussis primary immunisation. In addition, enhanced immune responses were observed to all serotypes included in the 13vPCV and Hib-PRP vaccines in children receiving the mixed wP/aP vaccination strategy versus those vaccinated with a standard aP-only schedule. Implications of all the available evidence: In settings transitioning from using wP to aP multi-component vaccines, infants receiving a mixed schedule (with wP as the first dose) can be expected have non-inferior, and possibly superior, antibody responses to concomitant vaccine antigens. To better understand the underlying mechanisms of our findings, the assessment of opsonophagocytic activity response rates and serotype-specific memory B cell immune responses to PCV antigens is required. Large population-based studies, particularly in countries where pneumococcal and Hib disease burdens remain high, should be conducted to determine if the observed effects on immune responses translate into differences in protection against disease.

  • Open Access

    Respiratory Syncytial Virus Reinfections in Children in Western Australia

    by David A. Foley, Cara A. Minney-Smith, Wei Hao Lee, Daniel B. Oakes, Briony Hazelton, Timothy J. Ford, Ushma Wadia, Chisha Sikazwe, Hannah C. Moore, Mark P. Nicol, et al.

    Respiratory syncytial virus (RSV) reinfection in children is poorly understood. We examined the incidence, characteristics, and outcomes of hospital-attended RSV reinfections in children <16 years in Western Australia between 2012 and 2022. Individuals with repeat RSV detections ≥56 days apart were identified using laboratory data. The incidence of reinfection in the first five years of life was estimated using the total birth population from 2012 to 2017. Clinical data on a subset of reinfection episodes were obtained from two metropolitan pediatric centers. A total of 466 children with hospital-attended reinfections were identified. The median interval between RSV detections was 460 days (interquartile range: 324, 812), with a reinfection rate of 95 per 100,000 individuals (95% confidence interval: 82, 109). Reinfection was most common in children who experienced their first RSV detection <6 months of age. Predisposing factors were identified in 56% of children; children with predisposing factors were older at first and second detections, were more likely to be admitted, and had a longer length of stay. This study highlights the significant burden of hospital-attended RSV reinfections in children with and without predisposing factors. Expanded surveillance with in-depth clinical data is required to further characterize the impact of RSV reinfection.